Literature DB >> 11811369

Endothelial factors and microvascular hypertensive disease.

D Rizzoni1, E Agabiti-Rosei.   

Abstract

This paper discusses the role of endothelial dysfunction in human hypertension, especially in relation to small resistance artery structure, as well as the effects of anti-hypertensive drugs on endothelial function of small arteries in human and experimental hypertension. A significant impairment of endothelial function was observed in human essential hypertension as well as in secondary forms of hypertension. No correlation was observed with vascular structure. In animal models of genetic hypertension there is substantial evidence for a beneficial effect of anti-hypertensive treatment with angiotensin converting enzyme (ACE) inhibitors, calcium entry blockers and angiotensin II receptor blockers on endothelial function in small resistance arteries. A significant improvement in endothelial dysfunction may be observed in hypertensive patients after prolonged treatment with ACE inhibitors (cilazapril, lisinopril), calcium entry blockers (nifedipine), and angiotensin II receptor blockers (losartan), while atenolol and hydrochlorotiazide proved to be ineffective in this regard despite similar blood pressure reductions. We conclude that: (i) the development of hypertension is usually associated with the presence of endothelial dysfunction in small resistance arteries of essential hypertensive patients; (ii) vascular structure does not seem to be the major determinant of endothelial function, at least in subcutaneous small resistance arteries; (iii) anti-hypertensive therapy with ACE inhibitors, angiotensin II receptor blockers and calcium entry blockers may improve endothelial function; (iv) a decrease in blood pressure seems to be necessary but not sufficient to obtain a beneficial effect on the endothelium in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11811369     DOI: 10.1097/00005344-200111002-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

2.  Rho-Kinase activity and cutaneous vasoconstriction is upregulated in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Lacy M Alexander
Journal:  Microvasc Res       Date:  2013-02-26       Impact factor: 3.514

3.  Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study.

Authors:  Cevad Sekuri; Ozgur Bayturan; Hakan Gocer; Talat Tavli; Ugur Kemal Tezcan
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.